Hypertrophic cardiomyopathy (HCM)

Hypertrophic cardiomyopathy, commonly known as HCM, is the most prevalent heart disease affecting cats and represents a significant cause of morbidity and sudden death in the feline population. This condition is characterized by abnormal thickening of the muscular walls of the left ventricle, the heart's primary pumping chamber, which occurs in the absence of other cardiovascular or systemic diseases that could explain the hypertrophy. HCM affects an estimated ten to fifteen percent of the general cat population, making it remarkably common compared to heart diseases in other species. While cats of any age, breed, or sex can develop HCM, it is most frequently diagnosed in young to middle-aged cats, typically between one and five years of age, and occurs more commonly in males than females.

The primary cause of HCM in cats is genetic, with mutations in genes encoding sarcomeric proteins being identified as responsible for familial forms of the disease in certain breeds. These genetic mutations lead to abnormal development of the heart muscle fibers, causing them to become disorganized and thickened. The condition has been well-documented in Maine Coons, Ragdolls, British Shorthairs, and several other purebred cats, though it also commonly affects domestic shorthairs and mixed-breed cats. The inheritance pattern is typically autosomal dominant with variable expression, meaning a cat needs only one copy of the abnormal gene to potentially develop the disease, though the severity can vary significantly even among affected family members.

The impact of HCM on a cat's health ranges from minimal in mildly affected individuals to life-threatening in severe cases. The thickened heart muscle becomes stiff and cannot relax properly between contractions, impairing the heart's ability to fill with blood during diastole. This leads to elevated pressures within the heart chambers and can result in congestive heart failure with fluid accumulation in or around the lungs. Perhaps the most feared complication of HCM is arterial thromboembolism, where blood clots form in the enlarged left atrium, break loose, and travel to block major arteries, most commonly causing sudden, painful paralysis of the hind legs. Additionally, HCM is a leading cause of sudden cardiac death in cats, occurring without any prior warning signs.

While there is currently no cure for HCM, the condition can often be managed effectively with appropriate treatment, and many affected cats live for years with good quality of life. Treatment focuses on reducing heart rate, promoting relaxation of the heart muscle, preventing blood clots, and managing heart failure if present. Early detection through regular cardiac screening, particularly in predisposed breeds, allows for intervention before severe complications develop. The prognosis varies widely depending on the severity of disease, presence of complications, and response to treatment, with some cats remaining stable for many years while others progress rapidly despite aggressive therapy. Regular veterinary monitoring is essential for adjusting treatment and detecting changes before they become critical.

The primary cause of hypertrophic cardiomyopathy in cats is genetic mutation affecting proteins essential for normal heart muscle function. In Maine Coon cats, a specific mutation in the MYBPC3 gene, which encodes cardiac myosin-binding protein C, has been identified as a major cause of familial HCM. A different mutation in the same gene has been found in Ragdoll cats with HCM. These mutations result in abnormal sarcomere proteins that interfere with normal muscle cell structure and function, leading to compensatory thickening of the heart muscle. While these specific mutations have been identified in certain breeds, many cases of HCM in both purebred and mixed-breed cats occur without identifiable mutations, suggesting that additional genetic factors remain to be discovered.

Genetic inheritance of HCM follows an autosomal dominant pattern with incomplete penetrance and variable expressivity. This means that a cat inheriting one copy of a mutant gene from either parent has the potential to develop HCM, but the actual expression of disease varies significantly. Some cats with the genetic mutation develop severe disease at a young age, while others may have only mild thickening that never causes clinical problems. Factors influencing this variability likely include modifier genes, environmental influences, and random developmental factors. Homozygous cats, those inheriting the mutation from both parents, typically develop more severe disease earlier in life, with Maine Coons homozygous for the MYBPC3 mutation often showing significant cardiac changes by one year of age.

While genetics represent the primary cause, certain environmental and physiological factors may influence the development or severity of HCM. Hypertension from any cause can produce secondary cardiac hypertrophy that mimics or exacerbates primary HCM, making blood pressure assessment important in all cats with ventricular thickening. Hyperthyroidism causes cardiac changes including ventricular hypertrophy, and must be ruled out in older cats presenting with heart disease. Chronic taurine deficiency, once a significant cause of feline dilated cardiomyopathy, has been largely eliminated since taurine supplementation became standard in commercial cat foods. Obesity and sedentary lifestyle have not been definitively linked to HCM development in cats but may affect overall cardiovascular health.

Risk factors for HCM extend beyond specific genetic mutations. Male cats are more commonly and often more severely affected than females, though the reasons for this sex predilection remain unclear. Age influences disease expression, with most cats developing detectable changes between one and five years of age, though disease can appear at any age from kittenhood to the geriatric years. Certain breeds carry dramatically increased risk due to founder effects and selective breeding, including Maine Coons, Ragdolls, British Shorthairs, Persians, Sphynx, Devon Rex, and Bengals. However, domestic shorthairs and mixed-breed cats also commonly develop HCM, likely reflecting the widespread distribution of causative mutations throughout the general cat population.

The mechanism by which genetic mutations lead to the characteristic heart muscle thickening involves complex cellular and molecular processes. Abnormal sarcomeric proteins disrupt the normal architecture and function of cardiac muscle cells, triggering compensatory responses that include increased protein synthesis and cell enlargement. The muscle cells, or myocytes, become hypertrophied and disorganized, losing their normal parallel arrangement and developing a characteristic pattern called myofiber disarray. Fibrosis, the deposition of excessive connective tissue, occurs between and around the abnormal muscle cells, further impairing heart function. These structural changes reduce ventricular compliance, meaning the chamber becomes stiff and cannot fill properly during diastole, which is the underlying problem causing most clinical manifestations of HCM.

Early warning signs of hypertrophic cardiomyopathy in cats are notoriously subtle and easily overlooked, contributing to the condition's reputation as a silent killer. Many cats with significant HCM show no obvious symptoms for months or years, with the disease detected only incidentally during routine examination when a heart murmur is heard. Some cats may display mild lethargy or slightly reduced activity that owners attribute to normal personality variation or aging. Subtle changes in breathing pattern, such as slightly increased respiratory rate at rest, may be present but are difficult for owners to detect. Cats are masters at hiding illness, and the gradual onset of HCM means that even attentive owners may not recognize early changes. This is why screening echocardiography is so important for at-risk breeds.

The most common symptoms that eventually lead to HCM diagnosis include respiratory signs resulting from congestive heart failure. Owners may notice their cat breathing faster than normal, particularly at rest or during sleep, with a normal resting respiratory rate being less than thirty breaths per minute. Open-mouth breathing or panting, which is abnormal for cats except after extreme exertion or in very hot conditions, indicates significant respiratory distress. Coughing is less common in cats than dogs with heart disease but may occur. Decreased appetite and weight loss may develop as the disease progresses. Some cats experience intermittent episodes of weakness or fainting, called syncope, particularly during exertion or excitement.

Behavioral changes associated with HCM often relate to the cat's reduced exercise tolerance and general malaise. Affected cats may show decreased interest in play and spend more time resting or sleeping. Some cats become more reclusive, hiding in unusual locations. Changes in grooming habits, either decreased grooming leading to a dull coat or in some cases excessive grooming from anxiety, may be observed. Appetite changes, including decreased food intake or changes in food preferences, can occur. Cats may seek cooler locations if they are experiencing respiratory difficulty. Changes in vocalization, particularly increased yowling at night, might indicate discomfort or distress.

Physical signs detectable during veterinary examination include heart murmurs, which occur in approximately fifty to seventy percent of cats with HCM, though their presence does not correlate well with disease severity. A gallop rhythm, an abnormal extra heart sound, indicates poor cardiac compliance and is a concerning finding. Arrhythmias, or abnormal heart rhythms, may be detected during auscultation. Increased respiratory rate and effort may be visible. In cats with congestive heart failure, lung sounds may be muffled or abnormal crackles may be heard. Weak femoral pulses may indicate reduced cardiac output. Cats with concurrent arterial thromboembolism will have absent pulses in affected limbs and may have cold, painful extremities.

Symptom progression in HCM can follow various patterns, and the disease course is often unpredictable. Some cats remain asymptomatic for years and may never develop clinical problems despite having significant cardiac changes. Others progress steadily over months to years, developing increasing evidence of congestive heart failure. Unfortunately, some cats experience sudden decline with acute heart failure, thromboembolism, or sudden death as the first obvious sign of disease. The transition from compensated to decompensated disease can occur gradually or precipitously, often triggered by stress, concurrent illness, anesthesia, or for no apparent reason. Understanding this variable progression emphasizes the importance of regular monitoring for cats with known HCM.

Emergency symptoms requiring immediate veterinary attention include severe difficulty breathing, open-mouth breathing, or any sign of respiratory distress. Sudden onset of hind limb paralysis or weakness with painful, cold legs indicates arterial thromboembolism and represents a medical emergency. Collapse, fainting, or unresponsiveness requires immediate evaluation. Blue or gray gums indicate severe oxygen deprivation. Cats with known HCM who show sudden worsening of any symptoms need prompt assessment. Acute lethargy with refusal to eat or move may indicate developing heart failure or other complications. Any suspicion of these serious complications warrants emergency veterinary care without delay, as outcomes are significantly better with rapid intervention.

The initial veterinary examination for suspected hypertrophic cardiomyopathy begins with a thorough history and complete physical assessment. The veterinarian will ask about any observed symptoms, changes in activity level, breathing patterns, and appetite. Physical examination focuses heavily on cardiovascular assessment, including careful auscultation to detect heart murmurs, gallop rhythms, or arrhythmias. The lungs are auscultated for abnormal sounds that might indicate fluid accumulation. Femoral pulse quality is assessed, and respiratory rate and effort are evaluated. Body condition and hydration status are noted. The veterinarian may also perform a fundic examination to look for signs of hypertensive retinopathy if hypertension is a concern. Blood pressure measurement helps rule out hypertension as a cause or contributor to cardiac changes.

Echocardiography, or cardiac ultrasound, is the gold standard diagnostic test for HCM and is essential for confirming the diagnosis and assessing severity. This non-invasive imaging study allows detailed visualization of cardiac structure and function. Key findings in HCM include increased thickness of the left ventricular wall and interventricular septum, typically measuring greater than six millimeters in diastole. The pattern of thickening may be symmetric or asymmetric, with some cats showing preferential hypertrophy of particular regions such as the septum or papillary muscles. Left atrial enlargement is an important prognostic indicator, as a larger left atrium correlates with increased risk of congestive heart failure and thromboembolism. Doppler assessment evaluates blood flow patterns and can detect dynamic outflow obstruction. Echocardiography also helps distinguish HCM from other forms of cardiomyopathy.

Additional diagnostic tests support the evaluation and help rule out secondary causes of ventricular hypertrophy. Complete blood count and serum chemistry panel assess overall health and organ function. Thyroid hormone measurement is essential in middle-aged to older cats to rule out hyperthyroidism, which can cause secondary cardiac changes. Blood pressure measurement helps identify hypertension, another cause of ventricular thickening. Chest radiographs may be taken to evaluate heart size and shape and to assess the lungs for evidence of congestive heart failure. Electrocardiography documents heart rhythm and may reveal arrhythmias or conduction abnormalities. Cardiac biomarkers such as cardiac troponin I and NT-proBNP can provide additional information about cardiac health, with elevated levels suggesting myocardial stress or damage.

Confirming the diagnosis of primary HCM requires demonstrating characteristic echocardiographic changes in the absence of other conditions that could cause secondary hypertrophy. Hyperthyroidism and hypertension must be ruled out through appropriate testing. The pattern and distribution of hypertrophy, along with other echocardiographic features, help distinguish HCM from other cardiomyopathies. Genetic testing is available for the MYBPC3 mutations in Maine Coons and Ragdolls, though a negative result does not rule out HCM since other mutations may be present. Staging of disease severity considers the degree of hypertrophy, left atrial size, presence of systolic anterior motion of the mitral valve, and presence of congestive heart failure or arrhythmias. This staging guides treatment decisions and provides prognostic information. Repeat echocardiography at regular intervals monitors disease progression.

Emergency treatment for cats presenting in acute decompensation from HCM focuses on stabilizing the patient and addressing life-threatening complications. Cats in respiratory distress from congestive heart failure require supplemental oxygen, often provided through an oxygen cage to minimize handling stress. Diuretics, particularly furosemide, are administered to reduce fluid accumulation in the lungs or pleural space. Sedation with medications like butorphanol may help reduce anxiety and respiratory effort. Thoracentesis, the removal of fluid from around the lungs using a needle, provides immediate relief for cats with significant pleural effusion. Cats with arterial thromboembolism require pain management as an immediate priority, as this condition is extremely painful, along with supportive care while determining whether aggressive treatment is appropriate. Antiarrhythmic medications may be needed for cats with significant rhythm disturbances.

Medical management of HCM aims to slow disease progression, prevent complications, and manage symptoms when they develop. Beta-blockers such as atenolol are commonly prescribed to reduce heart rate, decrease myocardial oxygen demand, and improve diastolic filling time. Calcium channel blockers like diltiazem may be used alternatively or in combination to promote relaxation of the heart muscle. These medications are particularly beneficial for cats with dynamic outflow obstruction or significant tachycardia. ACE inhibitors such as enalapril or benazepril may be added, especially in cats with evidence of neurohumoral activation or renal effects of cardiac disease. Antithrombotic therapy is crucial for preventing blood clots in cats with significant left atrial enlargement, with clopidogrel being the most commonly used antiplatelet agent, sometimes combined with aspirin.

Surgical intervention plays a limited role in most cases of feline HCM, as the disease is generally managed medically. However, some specialized referral centers offer interventional procedures for cats with refractory dynamic left ventricular outflow obstruction, where a portion of the thickened septum is removed or ablated to reduce obstruction. This procedure is similar to septal myectomy performed in humans with obstructive HCM. Pacemaker implantation may be considered for cats with significant bradyarrhythmias or atrioventricular block. These advanced procedures require specialized equipment and expertise and are available only at certain referral hospitals. For most cats with HCM, medical management remains the mainstay of treatment.

Supportive care for cats with HCM addresses quality of life and comfort alongside medical therapy. Stress reduction is important, as stress can precipitate acute decompensation in cats with heart disease. Nutritional support ensures adequate caloric intake, with moderate sodium restriction often recommended though not as severely as once practiced. Weight management helps reduce cardiac workload in overweight cats. Careful monitoring of hydration is important, particularly in cats also receiving diuretics for heart failure. Environmental modifications to minimize exertion may include providing easily accessible food, water, and litter boxes. Regular gentle handling helps maintain the human-animal bond while respecting the cat's need for rest.

Alternative and complementary treatments have limited evidence supporting their use in feline HCM but may provide additional support. Omega-3 fatty acids have anti-inflammatory effects and may have mild antiarrhythmic properties. Taurine supplementation, while no longer necessary with modern commercial diets, ensures adequate levels of this essential amino acid for cardiac function. Coenzyme Q10 is sometimes recommended for cardiac support, though studies in cats are lacking. Herbal remedies and other supplements should be used cautiously and discussed with the veterinarian to avoid interactions with prescribed medications. Stress reduction through environmental enrichment, pheromone therapy, or behavioral interventions may benefit cats with heart disease. The primary treatment remains conventional medical therapy.

Treatment decisions in HCM consider multiple factors unique to each patient. The stage of disease, presence of symptoms, echocardiographic findings, and detection of arrhythmias all influence medication selection and monitoring intensity. Cost considerations are relevant, as treatment often requires lifelong medication and regular monitoring with echocardiography. Some cats are difficult to medicate, and compounded flavored formulations or transdermal options may improve compliance. The expected benefit of treatment varies with disease stage, with asymptomatic cats potentially benefiting from delayed progression while symptomatic cats receive treatment to control signs and prevent complications. Open communication between owners and veterinarians about goals, expectations, and quality of life helps guide appropriate management decisions throughout the disease course.

The recovery timeline for cats with hypertrophic cardiomyopathy depends heavily on the presenting condition and complications. Cats diagnosed during routine screening without symptoms require no recovery per se but do need ongoing monitoring and potentially medication to prevent progression. Cats presenting in acute congestive heart failure may stabilize within one to three days with appropriate treatment, though they remain at risk for recurrence. Recovery from arterial thromboembolism, if the decision is made to pursue treatment, is prolonged and often incomplete, with motor function potentially taking weeks to months to improve and many cats not regaining full use of affected limbs. Cats recovering from any acute cardiac event require gradual return to normal activity and close monitoring for signs of recurrence.

Post-treatment care for cats with HCM involves regular medication administration, monitoring at home, and periodic veterinary assessment. Owners should become familiar with their cat's normal resting respiratory rate and count it regularly, as increasing rates may indicate developing heart failure. Activity restriction may be recommended, particularly for cats with severe disease or recent decompensation, though mild exercise is generally acceptable for stable patients. Medication compliance is essential, and owners should understand the purpose and importance of each prescribed drug. Follow-up echocardiography, typically every six to twelve months for stable patients, monitors disease progression and guides treatment adjustments. More frequent monitoring is needed for cats with advanced disease or recent changes.

Prognosis for cats with HCM varies widely based on disease stage, presence of complications, and response to treatment. Cats with mild disease discovered incidentally may have near-normal life expectancy and may never develop clinical problems. Median survival time from diagnosis ranges from approximately four years for mildly affected cats to less than one year for cats presenting with congestive heart failure or thromboembolism. The presence of severe left atrial enlargement, congestive heart failure, or arterial thromboembolism indicates more advanced disease and poorer prognosis. However, individual outcomes vary significantly, and some cats defy statistical predictions in both directions. Quality of life should be considered alongside quantity when discussing prognosis and treatment goals.

The long-term outlook for cats living with HCM requires acceptance of uncertainty and commitment to ongoing management. Some cats remain stable for many years with appropriate treatment and monitoring, living essentially normal lives with minimal impact from their heart disease. Others experience periodic decompensation requiring hospitalization and treatment adjustment. The risk of sudden death remains present, particularly for cats with significant arrhythmias or very severe disease, and this possibility should be discussed openly between owners and veterinarians. Regular veterinary care allows early detection of changes and timely intervention. Maintaining open communication about the cat's condition, quality of life, and owner observations helps optimize management and ensures that end-of-life decisions, when they become necessary, are made thoughtfully with the cat's best interests in mind.

Primary prevention of hypertrophic cardiomyopathy focuses on responsible breeding practices to reduce transmission of genetic mutations causing the disease. For breeds with identified mutations, such as Maine Coons and Ragdolls, genetic testing can identify carriers before breeding. Cats testing positive for the MYBPC3 mutation should ideally not be bred, or if breeding is considered essential for maintaining genetic diversity, should only be paired with mutation-negative partners, and offspring should be tested. Screening echocardiography performed annually or before breeding can identify affected cats before they reproduce, though this approach is imperfect as some cats develop disease later in life. Breeders should maintain open communication about health issues within their lines and avoid breeding from cats with affected relatives.

Environmental prevention strategies for HCM are limited since the disease is primarily genetic, but maintaining overall cardiac health may benefit susceptible cats. Minimizing stress through stable environments and appropriate environmental enrichment supports cardiovascular health. Maintaining a healthy body weight through appropriate diet and encouraging activity reduces overall cardiac workload. Ensuring cats receive complete and balanced nutrition, particularly adequate taurine, supports normal cardiac function. Avoiding exposure to cardiotoxic substances, though rare, protects heart muscle. While these measures cannot prevent genetically-determined HCM, they support overall cardiac health and may reduce the impact of disease in affected individuals.

Dietary approaches for cats at risk of HCM include feeding high-quality, nutritionally complete commercial diets that meet feline nutritional requirements. Adequate taurine content is essential, though all reputable commercial cat foods now contain sufficient levels. Moderate sodium intake is reasonable, avoiding high-sodium treats and table food. Maintaining appropriate caloric intake to prevent obesity reduces cardiovascular stress. Omega-3 fatty acid supplementation may provide cardiovascular benefits, though specific evidence for HCM prevention is lacking. For cats with diagnosed HCM, dietary modifications may be recommended as part of overall management. The primary dietary goal remains maintaining good overall nutrition and appropriate body condition.

Health maintenance through regular veterinary care is essential for detecting HCM early in predisposed cats. Annual wellness examinations including careful cardiac auscultation can detect heart murmurs that may indicate underlying disease. Echocardiographic screening is recommended for breeding cats from predisposed breeds and should be considered for pet cats from high-risk breeds, particularly Maine Coons, Ragdolls, British Shorthairs, and relatives of affected cats. Screening should begin around one year of age and be repeated annually or more frequently based on risk level and initial findings. Blood pressure screening helps identify hypertension that could contribute to cardiac changes. Early detection allows for early intervention and improved outcomes.

Early intervention when HCM is detected may slow disease progression and prevent complications, though the evidence for specific interventions in asymptomatic cats is evolving. Some cardiologists recommend starting beta-blockers or calcium channel blockers for cats with moderate to severe disease even before symptoms develop. Antithrombotic therapy is often initiated when significant left atrial enlargement is detected, given the substantial risk of thromboembolism. More frequent monitoring allows early detection of disease progression or developing complications. Owner education about warning signs ensures prompt attention when problems develop. Working with a veterinary cardiologist provides access to specialized expertise for managing complex cases and implementing the most current treatment strategies.

Daily management of a cat with hypertrophic cardiomyopathy centers on medication administration, environmental optimization, and careful observation. Most cats with symptomatic HCM require multiple daily medications, and establishing consistent routines improves compliance. Medications can often be given with food or treats, and compounded flavored formulations are available for cats who resist pilling. Owners should understand each medication's purpose and potential side effects. Daily observation of appetite, activity level, and breathing pattern helps detect changes early. Counting resting respiratory rate at least several times weekly provides objective data, with rates consistently above thirty breaths per minute warranting veterinary contact. Keeping a log of observations helps track trends over time.

Home environment modifications for cats with HCM aim to reduce stress and accommodate reduced exercise tolerance. Providing easily accessible resources, including food, water, and litter boxes on each floor of the home, eliminates the need for stair climbing. Quiet resting areas away from household commotion allow for undisturbed sleep. Temperature regulation is important, as cats with heart disease may be less tolerant of temperature extremes. Minimizing changes in the household environment reduces stress that could trigger decompensation. For households with multiple cats, ensuring the affected cat has access to resources without competition reduces social stress. Pheromone diffusers may help create a calming environment.

Maintaining quality of life for cats with HCM involves balancing activity restriction with mental stimulation and enjoyment. While strenuous exercise should be avoided, gentle play and interaction remain important for the cat's wellbeing. Interactive toys that encourage slow, calm play provide enrichment without excessive exertion. Comfortable resting spots, particularly elevated perches if the cat can access them safely, satisfy natural preferences. Continued social interaction with family members maintains the human-animal bond that is so important to cats. Grooming sessions provide physical contact and may help detect changes in body condition. The goal is a comfortable, enriched life adapted to the cat's cardiac limitations.

Ongoing monitoring and veterinary care are essential components of living with HCM. Regular recheck examinations, typically every three to six months for stable patients, allow assessment of disease status and treatment efficacy. Echocardiography performed every six to twelve months monitors structural changes and guides treatment adjustments. Blood work evaluates kidney function and medication effects. Owners should have clear guidelines for when to seek emergency care, including respiratory distress, collapse, sudden weakness or paralysis, or significant changes in condition. Establishing a relationship with an emergency veterinary clinic ensures after-hours care is available when needed. Some owners find home monitoring equipment, such as stethoscopes for checking heart rate, helpful for tracking their cat's condition.

Caregiver support is important when managing a cat with a chronic, potentially life-threatening condition. The emotional burden of knowing a beloved pet has heart disease and could experience sudden deterioration can be significant. Connecting with online communities of other owners managing feline heart disease provides emotional support and practical advice. Understanding the disease course and realistic expectations helps owners prepare for various outcomes. Financial planning for ongoing medication costs and periodic specialist visits reduces stress associated with treatment expenses. Open communication with the veterinary team ensures that treatment goals align with owner values and the cat's quality of life. Recognizing when the cat's comfort and dignity become priorities over aggressive treatment helps guide end-of-life decisions when they become necessary.

Several purebred cat breeds carry significantly elevated risk for hypertrophic cardiomyopathy due to genetic predispositions established through breeding practices. Maine Coon cats have the best-characterized genetic basis for HCM, with the MYBPC3-A31P mutation identified as a major cause. Studies suggest that approximately one-third of Maine Coons carry this mutation, though not all carriers develop clinical disease. Ragdoll cats carry a different mutation in the same gene, MYBPC3-R820W, which is also associated with HCM, with prevalence estimates suggesting twenty to thirty percent of the breed may be affected. British Shorthair cats have high HCM prevalence, though the specific genetic cause has not been definitively identified. Persian and Himalayan cats, Sphynx cats, Devon Rex cats, and Bengal cats also show increased HCM rates.

Beyond the highest-risk breeds, HCM affects cats across virtually all breed backgrounds. Domestic shorthair and domestic longhair cats, despite being mixed breeds, commonly develop HCM, likely because causative mutations are widespread in the general cat population. American Shorthairs, Birmans, Burmese, Cornish Rex, Norwegian Forest Cats, and Scottish Folds have all been reported with HCM. Male cats are more commonly affected than females across all breeds, and neutered males appear to have higher rates than intact males, though the reasons for these sex differences remain unclear. The widespread occurrence of HCM across breeds emphasizes that this is truly a disease of cats in general, not limited to specific breeds.

Screening recommendations vary based on breed risk and breeding status. For Maine Coons and Ragdolls, genetic testing for known mutations should be performed before breeding, with positive cats ideally excluded from breeding programs. However, genetic testing alone is insufficient because cats with negative results may still develop HCM from other mutations. Echocardiographic screening before breeding and annually thereafter is recommended for all cats from high-risk breeds and breeding cats from any breed. Pet cats from high-risk breeds should have baseline echocardiography around one to two years of age with periodic rescreening based on initial findings. Prospective owners of high-risk breeds should inquire about cardiac screening in the parents and the prevalence of HCM in the breeding line. Breed clubs and registries are increasingly promoting cardiac screening as a standard of responsible breeding.

Hypertrophic cardiomyopathy frequently leads to secondary conditions that significantly impact affected cats. Congestive heart failure is the most common complication of advanced HCM, occurring when the stiff, thickened heart can no longer fill adequately and pressures back up into the lungs or pleural space. Arterial thromboembolism, particularly saddle thrombus affecting the hind legs, occurs in approximately twelve to fifteen percent of cats with HCM and represents a devastating complication with guarded prognosis. Cardiac arrhythmias, including ventricular and supraventricular rhythm disturbances, develop in some HCM cats and may contribute to sudden death. Systemic hypertension can coexist with HCM and worsen cardiac changes. These interrelated conditions often require simultaneous management, adding complexity to treatment planning.

Several conditions produce clinical signs or echocardiographic findings that may be confused with primary HCM, making accurate diagnosis important. Hypertensive heart disease causes ventricular thickening secondary to high blood pressure and must be ruled out through blood pressure measurement. Hyperthyroidism produces cardiac changes including ventricular hypertrophy and should be excluded through thyroid testing in all middle-aged to older cats with heart disease. Restrictive cardiomyopathy involves impaired diastolic function without marked hypertrophy and may represent a different stage or form of cardiomyopathy. Dilated cardiomyopathy, once common due to taurine deficiency, causes ventricular dilation rather than thickening but shares some clinical features. Accurate differentiation is important because treatment and prognosis differ among these conditions.

Potential complications of HCM beyond the major ones already discussed include progressive deterioration of cardiac function leading to refractory heart failure despite aggressive treatment. Chronic kidney disease may develop secondary to reduced cardiac output affecting renal perfusion, or may be unmasked by treatments such as diuretics that are necessary for heart failure management. Pulmonary hypertension can develop secondary to left heart disease and further complicates management. Weight loss and muscle wasting from cardiac cachexia affect some cats with advanced disease. Secondary hepatic congestion from right-sided heart involvement may impair liver function. Recognizing these potential complications helps guide monitoring and allows early intervention when they develop.